Portal de Periódicos da CAPES

De-Escalation Strategies in HPV-Associated Oropharynx Cancer—Are we Putting the Cart Before the Horse?

2019; Elsevier BV; Volume: 104; Issue: 4 Linguagem: Inglês

10.1016/j.ijrobp.2019.02.054

1879-355X

Carryn M. Anderson, Randall J. Kimple, Alexander Lin, Sana D. Karam, Danielle N. Margalit, Melvin L.K. Chua,

Lung Cancer Treatments and Mutations

Let's get to the punchline because it is a big one: Radiation therapy plus cetuximab led to inferior overall survival (OS) in human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC). It is in light of the recently published results from Radiation Therapy Oncology Group (RTOG) 1016 and De-ESCALaTE HPV that we scope this issue's Oncology Scan to discuss the populist view that has prevailed among the head and neck cancer community for some time now: treatment de-intensification in HPV-positive oropharyngeal SCC (OPSCC).